Cargando…

The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials

Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis. Methods: The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Rong, Lin, Fei, Yu, Bin, Qiu, Jingyue, Zheng, Lingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554268/
https://www.ncbi.nlm.nih.gov/pubmed/36249780
http://dx.doi.org/10.3389/fphar.2022.975578
_version_ 1784806654948147200
author He, Rong
Lin, Fei
Yu, Bin
Qiu, Jingyue
Zheng, Lingli
author_facet He, Rong
Lin, Fei
Yu, Bin
Qiu, Jingyue
Zheng, Lingli
author_sort He, Rong
collection PubMed
description Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis. Methods: The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26 March 2022. Only randomized controlled trials (RCTs) that evaluated delafloxacin and comparator antibiotics for treating acute bacterial infections in adult patients were included. The clinical cure rate and microbiological eradication rate at the posttreatment evaluation, while the secondary outcomes included the risk of adverse events (AEs). Results: In total, six randomized controlled trials (RCTs) involving 3,019 patients with acute bacterial infection were included. There were no significant differences in the clinical cure rate between delafloxacin and comparators (OR = 1.06%, 95% CI = 0.89–1.26, I(2) = 0%). Overall, the results showed that delafloxacin had a microbiological eradication rate (documented and presumed) similar to the comparators (OR = 1.33%, 95% CI = 0.94–1.88, I(2) = 0%) in the pooled analysis of the six studies. Any treatment-emergent adverse events (TEAEs) did not show significant differences between delafloxacin and the comparators (OR = 0.93%, 95% CI = 0.80–1.08, I(2) = 75%). Serious adverse events (SAEs) did not differ between the delafloxacin and comparators (OR = 0.94%, 95% CI = 0.67–1.32, I(2) = 0%). The results of gastrointestinal disorders were (OR = 1.26%, 95% CI = 1.01–1.56, I(2) = 89%), and nausea, vomiting, and diarrhea were (OR = 0.77%, 95% CI = 0.45–1.34, I(2) = 79%), (OR = 1.00%, 95% CI = 0.74–1.36, I(2) = 72%), and (OR = 2.10%, 95% CI = 1.70–2.96, I(2) = 0%), respectively. The results showed that there was no significant difference in the incidence of nausea and vomiting between delafloxacin and the comparator, but the incidence of diarrhea was higher. The analysis of neurological disorders indicated that the incidence of nervous system disorders was lower in the delafloxacin group (OR = 0.71%, 95% CI = 0.50–1.01, I(2) = 52%). Conclusion: The clinical efficacy, microbiological eradication rate and the incidence of AEs of delafloxacin in the treatment of acute bacterial infections were similar to those of the comparators, as an alternative therapeutic agent.
format Online
Article
Text
id pubmed-9554268
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95542682022-10-13 The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials He, Rong Lin, Fei Yu, Bin Qiu, Jingyue Zheng, Lingli Front Pharmacol Pharmacology Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis. Methods: The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26 March 2022. Only randomized controlled trials (RCTs) that evaluated delafloxacin and comparator antibiotics for treating acute bacterial infections in adult patients were included. The clinical cure rate and microbiological eradication rate at the posttreatment evaluation, while the secondary outcomes included the risk of adverse events (AEs). Results: In total, six randomized controlled trials (RCTs) involving 3,019 patients with acute bacterial infection were included. There were no significant differences in the clinical cure rate between delafloxacin and comparators (OR = 1.06%, 95% CI = 0.89–1.26, I(2) = 0%). Overall, the results showed that delafloxacin had a microbiological eradication rate (documented and presumed) similar to the comparators (OR = 1.33%, 95% CI = 0.94–1.88, I(2) = 0%) in the pooled analysis of the six studies. Any treatment-emergent adverse events (TEAEs) did not show significant differences between delafloxacin and the comparators (OR = 0.93%, 95% CI = 0.80–1.08, I(2) = 75%). Serious adverse events (SAEs) did not differ between the delafloxacin and comparators (OR = 0.94%, 95% CI = 0.67–1.32, I(2) = 0%). The results of gastrointestinal disorders were (OR = 1.26%, 95% CI = 1.01–1.56, I(2) = 89%), and nausea, vomiting, and diarrhea were (OR = 0.77%, 95% CI = 0.45–1.34, I(2) = 79%), (OR = 1.00%, 95% CI = 0.74–1.36, I(2) = 72%), and (OR = 2.10%, 95% CI = 1.70–2.96, I(2) = 0%), respectively. The results showed that there was no significant difference in the incidence of nausea and vomiting between delafloxacin and the comparator, but the incidence of diarrhea was higher. The analysis of neurological disorders indicated that the incidence of nervous system disorders was lower in the delafloxacin group (OR = 0.71%, 95% CI = 0.50–1.01, I(2) = 52%). Conclusion: The clinical efficacy, microbiological eradication rate and the incidence of AEs of delafloxacin in the treatment of acute bacterial infections were similar to those of the comparators, as an alternative therapeutic agent. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9554268/ /pubmed/36249780 http://dx.doi.org/10.3389/fphar.2022.975578 Text en Copyright © 2022 He, Lin, Yu, Qiu and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
He, Rong
Lin, Fei
Yu, Bin
Qiu, Jingyue
Zheng, Lingli
The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
title The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
title_full The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
title_fullStr The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
title_full_unstemmed The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
title_short The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
title_sort efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: a systematic review and meta-analysis of randomized controlled trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554268/
https://www.ncbi.nlm.nih.gov/pubmed/36249780
http://dx.doi.org/10.3389/fphar.2022.975578
work_keys_str_mv AT herong theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT linfei theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT yubin theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT qiujingyue theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT zhenglingli theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT herong efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT linfei efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT yubin efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT qiujingyue efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials
AT zhenglingli efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials